X
 
(PPHM, OWW, DSCO) CRWENewswire Stocks In Action
J'aime
755
0
Publiée le 6 décembre 2011
Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients.
Peregrine Pharmaceuticals Inc - PPHM - reported preliminary results related with its Bavituximab from a randomized Phase II trial showing a 50% improvement in overall tumor response rates in non-small cell lung cancer patients. ( moins )
Tags:
Expliquer pourquoi ce vidéo devrait être retiré ou reclassé.